The TKI era was associated with a reduced cardiovascular mortality compared with the pre-TKI era among patients with chronic myeloid leukemia (HR 0.72; 95% CI 0.59-0.89).
Cohort
Yes
Does the TKI era reduce cardiovascular disease specific mortality in CML patients compared to the pre-TKI era?
The TKI era is associated with reduced cardiovascular mortality in CML patients compared to the pre-TKI era, despite emerging concerns about TKI-associated cardiovascular toxicity.
Hazard Ratio: 0.72 (95% CI 0.59–0.89)
Despite remarkable efficacy, there is an emerging concern regarding TKI-associated cardiovascular toxicity in CML. Long term follow-up studies on association between TKI therapy and cardiovascular outcome have been limited. CML patients were accessed from the SEER 18 database from 1992 to 2011. Cardiovascular disease (CVD) specific mortality was calculated comparing the pre-TKI era to the TKI era using the Fine-Gray competing risk model. Overall, the TKI era was associated with a reduced cardiovascular mortality compared with the pre-TKI era (HR = 0.72; 95%CI, 0.59-0.89). Our results argue for continued aggressive screening, identification and management of cardiovascular risk factors among all CML patients, especially the elderly, and further investigation into specific mechanisms, factors and predictors of risks in TKI-treated CML.
Wang et al. (2020) conducted a cohort in Chronic myeloid leukemia (CML). TKI era vs. pre-TKI era was evaluated on Cardiovascular disease (CVD) specific mortality (HR 0.72, 95% CI 0.59-0.89). The TKI era was associated with a reduced cardiovascular mortality compared with the pre-TKI era among patients with chronic myeloid leukemia (HR 0.72; 95% CI 0.59-0.89).